PTC Therapeutics, Inc. (PTCT) 10-Year Financial Performance & Capital Metrics

PTCT •

HealthcareBiotechnologyCommercial Rare Disease Biopharma

AboutPTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.Show more

Revenue $1.73B +114.5%
EBITDA $867M +482.1%
Net Income $683M +287.9%
EPS (Diluted) 7.78 +264.5%
Gross Margin -
EBITDA Margin 50.09% +278.1%
Operating Margin 50.09% +233.6%
Net Margin 39.44% +187.6%
ROE -
ROIC -
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y sales CAGR of 35.4%

✗Weaknesses

✗Shares diluted 14.9% in last year

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y46.99%

5Y35.37%

3Y35.3%

TTM97.54%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM265.87%

EPS CAGR

10Y-

5Y-

3Y-

TTM244.11%

ROCE

10Y Avg-19.52%

5Y Avg-11.46%

3Y Avg-0.73%

Latest56.77%

Peer Comparison

Commercial Rare Disease Biopharma

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
CORTCorcept Therapeutics Incorporated	3.78B	35.70	43.54	12.79%	13.01%	15.3%	3.75%	0.01
BMRNBioMarin Pharmaceutical Inc.	11.86B	61.73	34.29		10.83%	5.73%	6.11%	0.10
VRTXVertex Pharmaceuticals Incorporated	126.19B	496.83	32.43	8.9%	31.35%	21.22%	2.53%	0.20
CPRXCatalyst Pharmaceuticals, Inc.	2.83B	23.08	13.74	19.78%	36.39%	22.46%	7.38%	0.00
HRMYHarmony Biosciences Holdings, Inc.	1.65B	28.54	10.53	21.51%	18.27%	18.24%	21.12%	0.02
PTCTPTC Therapeutics, Inc.	5.45B	68.19	8.76	114.51%	42.25%
BCRXBioCryst Pharmaceuticals, Inc.	1.86B	8.75	7.23	94.1%	30.16%		18.63%
RAREUltragenyx Pharmaceutical Inc.	2.26B	23.39	-3.72	29.01%	-91.95%	-35.88%		0.15

Profit & Loss

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Sales/Revenue+	82.7M	194.39M	264.73M	306.98M	380.77M	538.59M	698.8M	937.82M	806.78M	1.73B
Revenue Growth %	124.95%	135.04%	36.19%	15.96%	24.04%	41.45%	29.75%	34.2%	-13.97%	114.51%
Cost of Goods Sold+	117.63M	4.58M	12.67M	12.13M	18.94M	32.33M	44.68M	65.49M	57.4M	0
COGS % of Revenue	142.23%	2.35%	4.79%	3.95%	4.97%	6%	6.39%	6.98%	7.11%	-
Gross Profit+	-34.93M	189.81M	252.06M	294.85M	361.82M	506.26M	654.12M	872.34M	749.38M	0
Gross Margin %	-42.23%	97.65%	95.21%	96.05%	95.03%	94%	93.61%	93.02%	92.89%	-
Gross Profit Growth %	58.93%	643.45%	32.79%	16.97%	22.72%	39.92%	29.21%	33.36%	-14.09%	-100%
Operating Expenses+	214.76M	254.11M	348.41M	536M	793.59M	880.71M	1.1B	1.31B	1.05B	863.72M
OpEx % of Revenue	259.67%	130.72%	131.61%	174.61%	208.42%	163.52%	157.63%	139.88%	130.39%	49.91%
Selling, General & Admin	97.13M	121.27M	153.55M	202.54M	245.16M	285.77M	326M	332.54M	300.91M	347.14M
SG&A % of Revenue	117.44%	62.38%	58%	65.98%	64.39%	53.06%	46.65%	35.46%	37.3%	20.06%
Research & Development	117.63M	117.46M	171.98M	257.45M	477.64M	540.68M	651.5M	666.56M	534.48M	455.25M
R&D % of Revenue	142.23%	60.42%	64.96%	83.87%	125.44%	100.39%	93.23%	71.08%	66.25%	26.3%
Other Operating Expenses	-1.21M	-1.28M	129K	76.01M	70.78M	54.25M	124.04M	312.74M	216.56M	61.33M
Operating Income+	-132.06M	-64.29M	-115.69M	-241.16M	-431.77M	-374.44M	-447.41M	-439.5M	-302.57M	866.93M
Operating Margin %	-159.67%	-33.07%	-43.7%	-78.56%	-113.39%	-69.52%	-64.03%	-46.86%	-37.5%	50.09%
Operating Income Growth %	20.98%	51.32%	-79.94%	-108.46%	-79.04%	13.28%	-19.49%	1.77%	31.16%	386.52%
EBITDA+	-128.77M	-46.61M	-89.6M	-208.98M	-388.28M	-310.31M	-318.57M	-202.91M	-226.91M	866.93M
EBITDA Margin %	-155.7%	-23.98%	-33.84%	-68.08%	-101.97%	-57.61%	-45.59%	-21.64%	-28.13%	50.09%
EBITDA Growth %	21.6%	63.8%	-92.23%	-133.24%	-85.8%	20.08%	-2.66%	36.31%	-11.83%	482.07%
D&A (Non-Cash Add-back)	3.29M	17.68M	26.09M	32.18M	43.49M	64.13M	128.84M	236.59M	75.66M	0
EBIT	-132.06M	-64.29M	-115.56M	-227.44M	-346.58M	-432.32M	-496.62M	-566.93M	-196.13M	0
Net Interest Income+	-8.28M	-12.09M	-12.55M	-12.49M	-56.35M	-86.02M	-90.87M	-129.18M	-166.99M	0
Interest Income	0	0	0	0	0	0	0	0	0	0
Interest Expense	8.28M	12.09M	12.55M	12.49M	56.35M	86.02M	90.87M	129.18M	166.99M	-152.23M
Other Income/Expense	-9.48M	-13.37M	-12.43M	1.23M	28.84M	-143.9M	-140.08M	-256.61M	-60.55M	-170.32M
Pretax Income+	-141.54M	-77.67M	-128.11M	-239.93M	-402.93M	-518.34M	-587.49M	-696.11M	-363.12M	696.62M
Pretax Margin %	-171.14%	-39.95%	-48.39%	-78.16%	-105.82%	-96.24%	-84.07%	-74.23%	-45.01%	40.25%
Income Tax+	569K	1.33M	-29K	11.65M	35.23M	5.56M	-28.47M	-69.51M	176K	-13.97M
Effective Tax Rate %	100.4%	101.72%	99.98%	104.86%	108.74%	101.07%	95.15%	90.02%	100.05%	97.99%
Net Income+	-142.11M	-79M	-128.08M	-251.58M	-438.16M	-523.9M	-559.02M	-626.6M	-363.3M	682.64M
Net Margin %	-171.83%	-40.64%	-48.38%	-81.95%	-115.07%	-97.27%	-80%	-66.81%	-45.03%	39.44%
Net Income Growth %	16.63%	44.41%	-62.13%	-96.42%	-74.17%	-19.57%	-6.7%	-12.09%	42.02%	287.9%
Net Income (Continuing)	-142.11M	-79M	-128.08M	-251.58M	-438.16M	-523.9M	-559.02M	-626.6M	-363.3M	682.64M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-4.17	-2.02	-2.75	-4.27	-6.64	-7.43	-7.79	-8.37	-4.73	7.78
EPS Growth %	17.75%	51.56%	-36.14%	-55.27%	-55.5%	-11.9%	-4.85%	-7.45%	43.49%	264.48%
EPS (Basic)	-4.17	-2.02	-2.75	-4.27	-6.64	-7.43	-7.79	-8.37	-4.73	8.58
Diluted Shares Outstanding	34.04M	39.18M	46.58M	58.86M	66.03M	70.47M	71.73M	74.84M	76.85M	88.31M
Basic Shares Outstanding	34.04M	39.11M	46.58M	58.86M	66.03M	70.47M	71.73M	74.84M	76.85M	79.53M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Current Assets+	261.29M	249.06M	320.86M	779.28M	1.23B	954.37M	693.78M	1.22B	1.37B	2.27B
Cash & Short-Term Investments	231.67M	191.25M	227.59M	686.56M	1.1B	773.38M	410.7M	876.74M	1.14B	1.95B
Cash Only	231.67M	191.25M	227.59M	288.03M	208.81M	189.72M	279.83M	594M	779.71M	984.65M
Short-Term Investments	0	0	0	398.54M	894.84M	583.66M	130.87M	282.74M	359.99M	960.72M
Accounts Receivable	24.93M	40.39M	67.91M	55.54M	69.93M	110.45M	155.61M	160.82M	158.55M	181.62M
Days Sales Outstanding	110.02	75.85	93.63	66.03	67.03	74.85	81.28	62.59	71.73	38.3
Inventory	0	10.75M	16.12M	19.29M	18.7M	15.86M	21.81M	30.58M	23.19M	79.65M
Days Inventory Outstanding	-	857.59	464.3	580.06	360.28	179.02	178.16	170.43	147.49	-
Other Current Assets	4.69M	6.67M	9.25M	0	0	0	105.66M	150.49M	44.09M	67.31M
Total Non-Current Assets+	8.06M	142.59M	798.37M	844.5M	976.53M	983.69M	1.01B	677.07M	339.49M	624.82M
Property, Plant & Equipment	7.43M	8.38M	12.69M	35.24M	118.24M	130.01M	175.02M	178.99M	117.66M	135.42M
Fixed Asset Turnover	11.13x	23.21x	20.86x	8.71x	3.22x	4.14x	3.99x	5.24x	6.86x	12.78x
Goodwill	0	0	82.34M	82.34M	82.34M	82.34M	82.34M	82.34M	82.34M	82.34M
Intangible Assets	0	132.99M	701.03M	710.5M	715.33M	724.84M	705.89M	379.5M	118.79M	388.75M
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	630K	1.22M	2.3M	16.41M	60.62M	46.5M	48.58M	36.25M	20.7M	18.3M
Total Assets+	269.35M	391.65M	1.12B	1.62B	2.21B	1.94B	1.71B	1.9B	1.71B	2.9B
Asset Turnover	0.31x	0.50x	0.24x	0.19x	0.17x	0.28x	0.41x	0.49x	0.47x	0.60x
Asset Growth %	-26.82%	45.41%	185.77%	45.08%	36%	-12.24%	-11.99%	11.14%	-10.06%	70.01%
Total Current Liabilities+	49.62M	82.05M	166.8M	235.86M	277.33M	509.35M	406.24M	603.1M	580.98M	968.43M
Accounts Payable	6.3M	15.28M	6M	10.32M	18.66M	23.03M	27.27M	6.04M	17.27M	0
Days Payables Outstanding	19.54	1.22K	172.88	310.53	359.66	260.05	222.77	33.69	109.85	-
Short-Term Debt	0	0	11.67M	20M	0	208.83M	72.15M	194.31M	257.82M	302.12M
Deferred Revenue (Current)	1.59M	3.94M	3.72M	8.24M	4.15M	0	1.35M	801K	5.5M	2.04M
Other Current Liabilities	29.68M	45.12M	117.78M	120.16M	129.89M	118.86M	126.46M	139.82M	120.22M	664.27M
Current Ratio	5.27x	3.04x	1.92x	3.30x	4.44x	1.87x	1.71x	2.02x	2.35x	2.35x
Quick Ratio	5.27x	2.90x	1.83x	3.22x	4.37x	1.84x	1.65x	1.97x	2.31x	2.27x
Cash Conversion Cycle	-	-285.25	385.05	335.57	67.65	-6.18	36.67	199.33	109.38	-
Total Non-Current Liabilities+	100.14M	153.17M	601.7M	793.6M	1.45B	1.43B	1.65B	2.11B	2.22B	2.14B
Long-Term Debt	98.22M	144.97M	141.35M	293.86M	309.14M	956.59M	1.26B	1.9B	2.11B	96.58M
Capital Lease Obligations	0	0	0	9.02M	102.55M	93.67M	119.53M	114.81M	90.52M	0
Deferred Tax Liabilities	0	-3.94M	122.03M	130.86M	136.74M	137.11M	102.83M	55.91M	0	0
Other Non-Current Liabilities	335K	243K	328.6M	356.44M	900.53M	239.9M	166.64M	36.44M	22.23M	2.04B
Total Liabilities	149.76M	235.22M	768.5M	1.03B	1.73B	1.94B	2.05B	2.71B	2.8B	3.1B
Total Debt+	98.22M	144.97M	153.01M	328.03M	420.44M	1.27B	1.46B	2.23B	2.47B	398.7M
Net Debt	-133.45M	-46.27M	-74.57M	40M	211.63M	1.08B	1.18B	1.64B	1.69B	-585.95M
Debt / Equity	0.82x	0.93x	0.44x	0.55x	0.87x	882.73x	-	-	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	0.46x
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-0.68x
Interest Coverage	-15.96x	-5.32x	-9.21x	-19.31x	-7.66x	-4.35x	-4.92x	-3.40x	-1.81x	-
Total Equity+	119.58M	156.44M	350.73M	594.33M	481.98M	1.44M	-347.09M	-818.55M	-1.1B	-205.31M
Equity Growth %	-59.93%	30.82%	124.2%	69.46%	-18.9%	-99.7%	-24236.72%	-135.84%	-34.15%	81.3%
Book Value per Share	3.51	3.99	7.53	10.10	7.30	0.02	-4.84	-10.94	-14.29	-2.32
Total Shareholders' Equity	119.58M	156.44M	350.73M	594.33M	481.98M	1.44M	-347.09M	-818.55M	-1.1B	-205.31M
Common Stock	34K	42K	51K	62K	70K	71K	72K	75K	77K	80K
Retained Earnings	-735.11M	-814.11M	-938.92M	-1.19B	-1.63B	-2.1B	-2.66B	-3.28B	-3.65B	-2.96B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-1.49M	3.97M	1.46M	-10.58M	-60.96M	-24.28M	4.8M	-1.28M	-25.89M	10.5M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Cash from Operations+	-103.57M	-10.06M	-27.64M	-98.64M	-194.07M	-251.33M	-356.65M	-158.42M	-107.69M	0
Operating CF Margin %	-125.22%	-5.18%	-10.44%	-32.13%	-50.97%	-46.66%	-51.04%	-16.89%	-13.35%	-
Operating CF Growth %	16.71%	90.28%	-174.68%	-256.86%	-96.75%	-29.51%	-41.91%	55.58%	32.02%	100%
Net Income	-142.11M	-79M	-128.08M	-251.58M	-438.16M	-523.9M	-559.02M	-626.6M	-363.3M	0
Depreciation & Amortization	3.29M	17.68M	26.09M	32.18M	84.87M	64.13M	128.84M	236.59M	75.66M	0
Stock-Based Compensation	35.01M	30.56M	33.25M	42.13M	70.33M	103.51M	110.33M	131.21M	74.61M	73.74M
Deferred Taxes	-199K	199K	-490K	8.83M	5.87M	377K	-34.28M	-46.93M	-55.91M	0
Other Non-Cash Items	9.41M	7.27M	27.38M	49.37M	46.11M	128.33M	82.81M	151.32M	58.7M	-73.74M
Working Capital Changes	-8.96M	13.23M	14.21M	20.43M	36.91M	-23.79M	-85.33M	-4M	102.54M	0
Change in Receivables	-14.84M	-12.2M	-29.59M	11.53M	-10.48M	-44.99M	-48.47M	-1.54M	1.73M	0
Change in Inventory	893K	-6.45M	-5.82M	-3.46M	1.84M	1.8M	-6.67M	-8.18M	6.16M	0
Change in Payables	4.26M	24.01M	43.11M	13.75M	53.59M	23.41M	27.54M	0	0	45.49M
Cash from Investing+	104.48M	13.12M	-42.61M	-387.24M	-561.55M	219.18M	290.18M	-176.74M	44.18M	0
Capital Expenditures	-1.78M	-3.1M	-15.53M	-45.44M	-55.98M	-85.33M	-152.46M	-28.44M	-6.5M	0
CapEx % of Revenue	2.15%	1.6%	5.87%	14.8%	14.7%	15.84%	21.82%	3.03%	0.81%	-
Acquisitions	0	-77.16M	-48.89M	-4M	38.13M	57.12M	128.44M	0	0	0
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	106.26M	16.22M	13.38M	0	-38.13M	-57.12M	-128.44M	-92.18M	110.31M	0
Cash from Financing+	968K	44.22M	131.57M	613.21M	668.72M	20.88M	167.95M	646.4M	255.87M	0
Debt Issued (Net)	0	40M	0	267.6M	-46.16M	-2.22M	148.72M	-301.38M	-1.49M	0
Equity Issued (Net)	0	0	1000K	1000K	1000K	1000K	1000K	0	0	0
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	0	0	0	0	0	0	0	0	0	0
Other Financing	968K	4.22M	13.65M	21.85M	686.78M	0	-30.77M	947.78M	257.36M	0
Net Change in Cash	299K	53.47M	57.71M	126.03M	-79.22M	-19.09M	98.71M	314.36M	185.03M	0
Free Cash Flow+	-105.34M	-13.16M	-43.17M	-144.08M	-250.05M	-336.66M	-509.11M	-279.04M	-181.94M	0
FCF Margin %	-127.37%	-6.77%	-16.31%	-46.93%	-65.67%	-62.51%	-72.86%	-29.75%	-22.55%	-
FCF Growth %	17.09%	87.5%	-227.95%	-233.74%	-73.55%	-34.64%	-51.22%	45.19%	34.8%	100%
FCF per Share	-3.09	-0.34	-0.93	-2.45	-3.79	-4.78	-7.10	-3.73	-2.37	-
FCF Conversion (FCF/Net Income)	0.73x	0.13x	0.22x	0.39x	0.44x	0.48x	0.64x	0.25x	0.30x	-
Interest Paid	4.51M	6.27M	7.77M	7.69M	9.8M	9.59M	18.46M	36.13M	5.82M	0
Taxes Paid	943K	1.1M	1.58M	2.11M	26.4M	7.71M	4.92M	14.15M	17.55M	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-67.99%	-57.24%	-50.51%	-53.24%	-81.42%	-216.75%	-	-	-	-
Return on Invested Capital (ROIC)	-491.74%	-100.15%	-44.92%	-39.73%	-48.77%	-31.65%	-35.03%	-39.93%	-32.19%	-
Gross Margin	-42.23%	97.65%	95.21%	96.05%	95.03%	94%	93.61%	93.02%	92.89%	-
Net Margin	-171.83%	-40.64%	-48.38%	-81.95%	-115.07%	-97.27%	-80%	-66.81%	-45.03%	39.44%
Debt / Equity	0.82x	0.93x	0.44x	0.55x	0.87x	882.73x	-	-	-	-
Interest Coverage	-15.96x	-5.32x	-9.21x	-19.31x	-7.66x	-4.35x	-4.92x	-3.40x	-1.81x	-
FCF Conversion	0.73x	0.13x	0.22x	0.39x	0.44x	0.48x	0.64x	0.25x	0.30x	-
Revenue Growth	124.95%	135.04%	36.19%	15.96%	24.04%	41.45%	29.75%	34.2%	-13.97%	114.51%

US Stock Screener

...

PTC Therapeutics, Inc. (PTCT) 10-Year Financial Performance & Capital Metrics

PTCT •

HealthcareBiotechnologyCommercial Rare Disease Biopharma

Revenue $1.73B +114.5%
EBITDA $867M +482.1%
Net Income $683M +287.9%
EPS (Diluted) 7.78 +264.5%
Gross Margin -
EBITDA Margin 50.09% +278.1%
Operating Margin 50.09% +233.6%
Net Margin 39.44% +187.6%
ROE -
ROIC -
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y sales CAGR of 35.4%

✗Weaknesses

✗Shares diluted 14.9% in last year

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y46.99%

5Y35.37%

3Y35.3%

TTM97.54%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM265.87%

EPS CAGR

10Y-

5Y-

3Y-

TTM244.11%

ROCE

10Y Avg-19.52%

5Y Avg-11.46%

3Y Avg-0.73%

Latest56.77%

Peer Comparison

Commercial Rare Disease Biopharma

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
CORTCorcept Therapeutics Incorporated	3.78B	35.70	43.54	12.79%	13.01%	15.3%	3.75%	0.01
BMRNBioMarin Pharmaceutical Inc.	11.86B	61.73	34.29		10.83%	5.73%	6.11%	0.10
VRTXVertex Pharmaceuticals Incorporated	126.19B	496.83	32.43	8.9%	31.35%	21.22%	2.53%	0.20
CPRXCatalyst Pharmaceuticals, Inc.	2.83B	23.08	13.74	19.78%	36.39%	22.46%	7.38%	0.00
HRMYHarmony Biosciences Holdings, Inc.	1.65B	28.54	10.53	21.51%	18.27%	18.24%	21.12%	0.02
PTCTPTC Therapeutics, Inc.	5.45B	68.19	8.76	114.51%	42.25%
BCRXBioCryst Pharmaceuticals, Inc.	1.86B	8.75	7.23	94.1%	30.16%		18.63%
RAREUltragenyx Pharmaceutical Inc.	2.26B	23.39	-3.72	29.01%	-91.95%	-35.88%		0.15

Profit & Loss

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Sales/Revenue+	82.7M	194.39M	264.73M	306.98M	380.77M	538.59M	698.8M	937.82M	806.78M	1.73B
Revenue Growth %	124.95%	135.04%	36.19%	15.96%	24.04%	41.45%	29.75%	34.2%	-13.97%	114.51%
Cost of Goods Sold+	117.63M	4.58M	12.67M	12.13M	18.94M	32.33M	44.68M	65.49M	57.4M	0
COGS % of Revenue	142.23%	2.35%	4.79%	3.95%	4.97%	6%	6.39%	6.98%	7.11%	-
Gross Profit+	-34.93M	189.81M	252.06M	294.85M	361.82M	506.26M	654.12M	872.34M	749.38M	0
Gross Margin %	-42.23%	97.65%	95.21%	96.05%	95.03%	94%	93.61%	93.02%	92.89%	-
Gross Profit Growth %	58.93%	643.45%	32.79%	16.97%	22.72%	39.92%	29.21%	33.36%	-14.09%	-100%
Operating Expenses+	214.76M	254.11M	348.41M	536M	793.59M	880.71M	1.1B	1.31B	1.05B	863.72M
OpEx % of Revenue	259.67%	130.72%	131.61%	174.61%	208.42%	163.52%	157.63%	139.88%	130.39%	49.91%
Selling, General & Admin	97.13M	121.27M	153.55M	202.54M	245.16M	285.77M	326M	332.54M	300.91M	347.14M
SG&A % of Revenue	117.44%	62.38%	58%	65.98%	64.39%	53.06%	46.65%	35.46%	37.3%	20.06%
Research & Development	117.63M	117.46M	171.98M	257.45M	477.64M	540.68M	651.5M	666.56M	534.48M	455.25M
R&D % of Revenue	142.23%	60.42%	64.96%	83.87%	125.44%	100.39%	93.23%	71.08%	66.25%	26.3%
Other Operating Expenses	-1.21M	-1.28M	129K	76.01M	70.78M	54.25M	124.04M	312.74M	216.56M	61.33M
Operating Income+	-132.06M	-64.29M	-115.69M	-241.16M	-431.77M	-374.44M	-447.41M	-439.5M	-302.57M	866.93M
Operating Margin %	-159.67%	-33.07%	-43.7%	-78.56%	-113.39%	-69.52%	-64.03%	-46.86%	-37.5%	50.09%
Operating Income Growth %	20.98%	51.32%	-79.94%	-108.46%	-79.04%	13.28%	-19.49%	1.77%	31.16%	386.52%
EBITDA+	-128.77M	-46.61M	-89.6M	-208.98M	-388.28M	-310.31M	-318.57M	-202.91M	-226.91M	866.93M
EBITDA Margin %	-155.7%	-23.98%	-33.84%	-68.08%	-101.97%	-57.61%	-45.59%	-21.64%	-28.13%	50.09%
EBITDA Growth %	21.6%	63.8%	-92.23%	-133.24%	-85.8%	20.08%	-2.66%	36.31%	-11.83%	482.07%
D&A (Non-Cash Add-back)	3.29M	17.68M	26.09M	32.18M	43.49M	64.13M	128.84M	236.59M	75.66M	0
EBIT	-132.06M	-64.29M	-115.56M	-227.44M	-346.58M	-432.32M	-496.62M	-566.93M	-196.13M	0
Net Interest Income+	-8.28M	-12.09M	-12.55M	-12.49M	-56.35M	-86.02M	-90.87M	-129.18M	-166.99M	0
Interest Income	0	0	0	0	0	0	0	0	0	0
Interest Expense	8.28M	12.09M	12.55M	12.49M	56.35M	86.02M	90.87M	129.18M	166.99M	-152.23M
Other Income/Expense	-9.48M	-13.37M	-12.43M	1.23M	28.84M	-143.9M	-140.08M	-256.61M	-60.55M	-170.32M
Pretax Income+	-141.54M	-77.67M	-128.11M	-239.93M	-402.93M	-518.34M	-587.49M	-696.11M	-363.12M	696.62M
Pretax Margin %	-171.14%	-39.95%	-48.39%	-78.16%	-105.82%	-96.24%	-84.07%	-74.23%	-45.01%	40.25%
Income Tax+	569K	1.33M	-29K	11.65M	35.23M	5.56M	-28.47M	-69.51M	176K	-13.97M
Effective Tax Rate %	100.4%	101.72%	99.98%	104.86%	108.74%	101.07%	95.15%	90.02%	100.05%	97.99%
Net Income+	-142.11M	-79M	-128.08M	-251.58M	-438.16M	-523.9M	-559.02M	-626.6M	-363.3M	682.64M
Net Margin %	-171.83%	-40.64%	-48.38%	-81.95%	-115.07%	-97.27%	-80%	-66.81%	-45.03%	39.44%
Net Income Growth %	16.63%	44.41%	-62.13%	-96.42%	-74.17%	-19.57%	-6.7%	-12.09%	42.02%	287.9%
Net Income (Continuing)	-142.11M	-79M	-128.08M	-251.58M	-438.16M	-523.9M	-559.02M	-626.6M	-363.3M	682.64M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-4.17	-2.02	-2.75	-4.27	-6.64	-7.43	-7.79	-8.37	-4.73	7.78
EPS Growth %	17.75%	51.56%	-36.14%	-55.27%	-55.5%	-11.9%	-4.85%	-7.45%	43.49%	264.48%
EPS (Basic)	-4.17	-2.02	-2.75	-4.27	-6.64	-7.43	-7.79	-8.37	-4.73	8.58
Diluted Shares Outstanding	34.04M	39.18M	46.58M	58.86M	66.03M	70.47M	71.73M	74.84M	76.85M	88.31M
Basic Shares Outstanding	34.04M	39.11M	46.58M	58.86M	66.03M	70.47M	71.73M	74.84M	76.85M	79.53M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Current Assets+	261.29M	249.06M	320.86M	779.28M	1.23B	954.37M	693.78M	1.22B	1.37B	2.27B
Cash & Short-Term Investments	231.67M	191.25M	227.59M	686.56M	1.1B	773.38M	410.7M	876.74M	1.14B	1.95B
Cash Only	231.67M	191.25M	227.59M	288.03M	208.81M	189.72M	279.83M	594M	779.71M	984.65M
Short-Term Investments	0	0	0	398.54M	894.84M	583.66M	130.87M	282.74M	359.99M	960.72M
Accounts Receivable	24.93M	40.39M	67.91M	55.54M	69.93M	110.45M	155.61M	160.82M	158.55M	181.62M
Days Sales Outstanding	110.02	75.85	93.63	66.03	67.03	74.85	81.28	62.59	71.73	38.3
Inventory	0	10.75M	16.12M	19.29M	18.7M	15.86M	21.81M	30.58M	23.19M	79.65M
Days Inventory Outstanding	-	857.59	464.3	580.06	360.28	179.02	178.16	170.43	147.49	-
Other Current Assets	4.69M	6.67M	9.25M	0	0	0	105.66M	150.49M	44.09M	67.31M
Total Non-Current Assets+	8.06M	142.59M	798.37M	844.5M	976.53M	983.69M	1.01B	677.07M	339.49M	624.82M
Property, Plant & Equipment	7.43M	8.38M	12.69M	35.24M	118.24M	130.01M	175.02M	178.99M	117.66M	135.42M
Fixed Asset Turnover	11.13x	23.21x	20.86x	8.71x	3.22x	4.14x	3.99x	5.24x	6.86x	12.78x
Goodwill	0	0	82.34M	82.34M	82.34M	82.34M	82.34M	82.34M	82.34M	82.34M
Intangible Assets	0	132.99M	701.03M	710.5M	715.33M	724.84M	705.89M	379.5M	118.79M	388.75M
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	630K	1.22M	2.3M	16.41M	60.62M	46.5M	48.58M	36.25M	20.7M	18.3M
Total Assets+	269.35M	391.65M	1.12B	1.62B	2.21B	1.94B	1.71B	1.9B	1.71B	2.9B
Asset Turnover	0.31x	0.50x	0.24x	0.19x	0.17x	0.28x	0.41x	0.49x	0.47x	0.60x
Asset Growth %	-26.82%	45.41%	185.77%	45.08%	36%	-12.24%	-11.99%	11.14%	-10.06%	70.01%
Total Current Liabilities+	49.62M	82.05M	166.8M	235.86M	277.33M	509.35M	406.24M	603.1M	580.98M	968.43M
Accounts Payable	6.3M	15.28M	6M	10.32M	18.66M	23.03M	27.27M	6.04M	17.27M	0
Days Payables Outstanding	19.54	1.22K	172.88	310.53	359.66	260.05	222.77	33.69	109.85	-
Short-Term Debt	0	0	11.67M	20M	0	208.83M	72.15M	194.31M	257.82M	302.12M
Deferred Revenue (Current)	1.59M	3.94M	3.72M	8.24M	4.15M	0	1.35M	801K	5.5M	2.04M
Other Current Liabilities	29.68M	45.12M	117.78M	120.16M	129.89M	118.86M	126.46M	139.82M	120.22M	664.27M
Current Ratio	5.27x	3.04x	1.92x	3.30x	4.44x	1.87x	1.71x	2.02x	2.35x	2.35x
Quick Ratio	5.27x	2.90x	1.83x	3.22x	4.37x	1.84x	1.65x	1.97x	2.31x	2.27x
Cash Conversion Cycle	-	-285.25	385.05	335.57	67.65	-6.18	36.67	199.33	109.38	-
Total Non-Current Liabilities+	100.14M	153.17M	601.7M	793.6M	1.45B	1.43B	1.65B	2.11B	2.22B	2.14B
Long-Term Debt	98.22M	144.97M	141.35M	293.86M	309.14M	956.59M	1.26B	1.9B	2.11B	96.58M
Capital Lease Obligations	0	0	0	9.02M	102.55M	93.67M	119.53M	114.81M	90.52M	0
Deferred Tax Liabilities	0	-3.94M	122.03M	130.86M	136.74M	137.11M	102.83M	55.91M	0	0
Other Non-Current Liabilities	335K	243K	328.6M	356.44M	900.53M	239.9M	166.64M	36.44M	22.23M	2.04B
Total Liabilities	149.76M	235.22M	768.5M	1.03B	1.73B	1.94B	2.05B	2.71B	2.8B	3.1B
Total Debt+	98.22M	144.97M	153.01M	328.03M	420.44M	1.27B	1.46B	2.23B	2.47B	398.7M
Net Debt	-133.45M	-46.27M	-74.57M	40M	211.63M	1.08B	1.18B	1.64B	1.69B	-585.95M
Debt / Equity	0.82x	0.93x	0.44x	0.55x	0.87x	882.73x	-	-	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	0.46x
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-0.68x
Interest Coverage	-15.96x	-5.32x	-9.21x	-19.31x	-7.66x	-4.35x	-4.92x	-3.40x	-1.81x	-
Total Equity+	119.58M	156.44M	350.73M	594.33M	481.98M	1.44M	-347.09M	-818.55M	-1.1B	-205.31M
Equity Growth %	-59.93%	30.82%	124.2%	69.46%	-18.9%	-99.7%	-24236.72%	-135.84%	-34.15%	81.3%
Book Value per Share	3.51	3.99	7.53	10.10	7.30	0.02	-4.84	-10.94	-14.29	-2.32
Total Shareholders' Equity	119.58M	156.44M	350.73M	594.33M	481.98M	1.44M	-347.09M	-818.55M	-1.1B	-205.31M
Common Stock	34K	42K	51K	62K	70K	71K	72K	75K	77K	80K
Retained Earnings	-735.11M	-814.11M	-938.92M	-1.19B	-1.63B	-2.1B	-2.66B	-3.28B	-3.65B	-2.96B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-1.49M	3.97M	1.46M	-10.58M	-60.96M	-24.28M	4.8M	-1.28M	-25.89M	10.5M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Cash from Operations+	-103.57M	-10.06M	-27.64M	-98.64M	-194.07M	-251.33M	-356.65M	-158.42M	-107.69M	0
Operating CF Margin %	-125.22%	-5.18%	-10.44%	-32.13%	-50.97%	-46.66%	-51.04%	-16.89%	-13.35%	-
Operating CF Growth %	16.71%	90.28%	-174.68%	-256.86%	-96.75%	-29.51%	-41.91%	55.58%	32.02%	100%
Net Income	-142.11M	-79M	-128.08M	-251.58M	-438.16M	-523.9M	-559.02M	-626.6M	-363.3M	0
Depreciation & Amortization	3.29M	17.68M	26.09M	32.18M	84.87M	64.13M	128.84M	236.59M	75.66M	0
Stock-Based Compensation	35.01M	30.56M	33.25M	42.13M	70.33M	103.51M	110.33M	131.21M	74.61M	73.74M
Deferred Taxes	-199K	199K	-490K	8.83M	5.87M	377K	-34.28M	-46.93M	-55.91M	0
Other Non-Cash Items	9.41M	7.27M	27.38M	49.37M	46.11M	128.33M	82.81M	151.32M	58.7M	-73.74M
Working Capital Changes	-8.96M	13.23M	14.21M	20.43M	36.91M	-23.79M	-85.33M	-4M	102.54M	0
Change in Receivables	-14.84M	-12.2M	-29.59M	11.53M	-10.48M	-44.99M	-48.47M	-1.54M	1.73M	0
Change in Inventory	893K	-6.45M	-5.82M	-3.46M	1.84M	1.8M	-6.67M	-8.18M	6.16M	0
Change in Payables	4.26M	24.01M	43.11M	13.75M	53.59M	23.41M	27.54M	0	0	45.49M
Cash from Investing+	104.48M	13.12M	-42.61M	-387.24M	-561.55M	219.18M	290.18M	-176.74M	44.18M	0
Capital Expenditures	-1.78M	-3.1M	-15.53M	-45.44M	-55.98M	-85.33M	-152.46M	-28.44M	-6.5M	0
CapEx % of Revenue	2.15%	1.6%	5.87%	14.8%	14.7%	15.84%	21.82%	3.03%	0.81%	-
Acquisitions	0	-77.16M	-48.89M	-4M	38.13M	57.12M	128.44M	0	0	0
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	106.26M	16.22M	13.38M	0	-38.13M	-57.12M	-128.44M	-92.18M	110.31M	0
Cash from Financing+	968K	44.22M	131.57M	613.21M	668.72M	20.88M	167.95M	646.4M	255.87M	0
Debt Issued (Net)	0	40M	0	267.6M	-46.16M	-2.22M	148.72M	-301.38M	-1.49M	0
Equity Issued (Net)	0	0	1000K	1000K	1000K	1000K	1000K	0	0	0
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	0	0	0	0	0	0	0	0	0	0
Other Financing	968K	4.22M	13.65M	21.85M	686.78M	0	-30.77M	947.78M	257.36M	0
Net Change in Cash	299K	53.47M	57.71M	126.03M	-79.22M	-19.09M	98.71M	314.36M	185.03M	0
Free Cash Flow+	-105.34M	-13.16M	-43.17M	-144.08M	-250.05M	-336.66M	-509.11M	-279.04M	-181.94M	0
FCF Margin %	-127.37%	-6.77%	-16.31%	-46.93%	-65.67%	-62.51%	-72.86%	-29.75%	-22.55%	-
FCF Growth %	17.09%	87.5%	-227.95%	-233.74%	-73.55%	-34.64%	-51.22%	45.19%	34.8%	100%
FCF per Share	-3.09	-0.34	-0.93	-2.45	-3.79	-4.78	-7.10	-3.73	-2.37	-
FCF Conversion (FCF/Net Income)	0.73x	0.13x	0.22x	0.39x	0.44x	0.48x	0.64x	0.25x	0.30x	-
Interest Paid	4.51M	6.27M	7.77M	7.69M	9.8M	9.59M	18.46M	36.13M	5.82M	0
Taxes Paid	943K	1.1M	1.58M	2.11M	26.4M	7.71M	4.92M	14.15M	17.55M	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-67.99%	-57.24%	-50.51%	-53.24%	-81.42%	-216.75%	-	-	-	-
Return on Invested Capital (ROIC)	-491.74%	-100.15%	-44.92%	-39.73%	-48.77%	-31.65%	-35.03%	-39.93%	-32.19%	-
Gross Margin	-42.23%	97.65%	95.21%	96.05%	95.03%	94%	93.61%	93.02%	92.89%	-
Net Margin	-171.83%	-40.64%	-48.38%	-81.95%	-115.07%	-97.27%	-80%	-66.81%	-45.03%	39.44%
Debt / Equity	0.82x	0.93x	0.44x	0.55x	0.87x	882.73x	-	-	-	-
Interest Coverage	-15.96x	-5.32x	-9.21x	-19.31x	-7.66x	-4.35x	-4.92x	-3.40x	-1.81x	-
FCF Conversion	0.73x	0.13x	0.22x	0.39x	0.44x	0.48x	0.64x	0.25x	0.30x	-
Revenue Growth	124.95%	135.04%	36.19%	15.96%	24.04%	41.45%	29.75%	34.2%	-13.97%	114.51%

PTC Therapeutics, Inc. (PTCT) 10-Year Financial Performance & Capital Metrics

Key Insights

✓Strengths

✗Weaknesses

Price & Volume

Growth Metrics

Revenue CAGR

Profit (Net Income) CAGR

EPS CAGR

ROCE

Peer Comparison

Compare PTCT vs Peers

vs AGIO

vs VRTX

Compare Top 5

Profit & Loss

Balance Sheet

Cash Flow

Key Ratios

Deep Dive Analysis

Valuation Overview

Total Return Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

PTC Therapeutics, Inc. (PTCT) 10-Year Financial Performance & Capital Metrics

Key Insights

✓Strengths

✗Weaknesses

Price & Volume

Growth Metrics

Revenue CAGR

Profit (Net Income) CAGR

EPS CAGR

ROCE

Peer Comparison

Compare PTCT vs Peers

vs AGIO

vs VRTX

Compare Top 5

Profit & Loss

Balance Sheet

Cash Flow

Key Ratios

Deep Dive Analysis

Valuation Overview

Total Return Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios